In March 2017, world's first clinical study as a part of a clinical research project aimed at establishing an allogeneic induced pluripotent stem cell (iPS Cell)-based treatment has been conducted, and such iPS Cells were generated from other donors and stockpiled by Kyoto University's Center for iPS Cell Research and Application (CiRA). We feel iPS Cell technologies start blooming in regenerative medicine. On the other hand, iPS Cell technologies in pharmaceutical development enjoy the practical applications, as cardiomyocytes, neural cells and others derived from iPS Cells are commercially available and widely used by many companies in the world for drug discoveries.
iPS Academia Japan, Inc. celebrates its 9th anniversary on June 2017, and since foundation, we have concluded license agreements with more than 100 entities in Japan and 60 entities in other countries. We deeply appreciate your attention to iPS Cell related patents and your understanding to our patent licensing operation.
Finally, since we will continue our efforts to license our iPS Cell related patents to boost the industrialization of iPS Cell technology, we are always happy to have your inquiries, and also, we would appreciate all of your feedbacks and supports to our activities.
President & CEO
iPS Academia Japan, Inc.